IRTC · iRhythm Holdings, Inc.
$128.25
+0.27 (+0.21%)
At close · Aug 21
Market Cap
$4.11B
Shares
32.96M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$127.98
Open$124.59
Day$123.97–128.81
52W close$101.79–189.25
Avg vol 30d638K
Short int3.2M · 9.7% float · 6.6d
Short vol63%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
+9%
above
RSI (14)
58
neutral
MACD trend
Negative
52-week position
30%
mid-range
Momentum
relative strength
1-month return
+19%
trailing
6-month return
−4%
trailing
YTD return
−28%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $117 › 200d $138 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +45 funds added
Insider flow
Distributing
Net -$7.9M over 90 days · 100% sells
Short interest
Falling
9.75% of float · ▼ -6.3% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
303 holders — mid 3-yr range
Squeeze score
70
high risk · 0–100
Fundamentals
Revenue growth
+26%
Y/Y
Gross margin
71%
expanding
EPS growth
+62%
Y/Y
Free cash flow
$34.5M
Balance sheet
$201.1M
net cash
Quant / Vol
risk profile
Volatility
43%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
full year 2026
Revenue
Initiated
$880M – $890M
prior FY $747.14M
midpoint +18.5% Y/Y
Adjusted EBITDA margin
Non-GAAP
Initiated
13% – 14%
2027
Adjusted EBITDA margin
Non-GAAP
15%
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2026
Adjusted EBITDA margin
· second quarter, 2026
11.5% – 12.5%
Guided vs delivered
· last 3 settled
Revenue
full year 2025
guided $735M – $740M
$747.14M
Beat +1.3%
Full year revenue
full year 2024
guided $575M – $585M
$591.84M
Beat +2.0%
Full year revenue
full year 2023
guided $487.5M – $490M
$492.68M
Beat +0.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
58
Neutral
MACD trend
Negative
Bearish
52-week position
30%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $117 › 200d $138 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +45 funds added
Insider flow
Distributing
Net -$7.9M over 90 days · 100% sells
Short interest
Falling
9.75% of float · ▼ -6.3% MoM · 6.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
303 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $102
Now $128 · 30%
Range high $189
vs 200-day avg -7%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $43.3M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net loss, as reported -381K
+3.29M Interest expense
-4.78M Interest income
-822K Changes in fair value of strategic investments
+0K Income tax provision (benefit)
+5.22M Depreciation and amortization
+20.04M Stock-based compensation
+0K Impairment charges
+1.16M Business transformation costs
+4.93M Intellectual property litigation expenses
+13.95M Litigation settlements
+686K Cybersecurity incident
= Adjusted EBITDA 43.3M
|
|||
| Adjusted EBITDA margin non-GAAP | 19.3% | Q2 2026 | — |
|
|
|||
| Free cash flow non-GAAP | $34.5M | Full Year 2025 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 80.86M
-46.34M Purchases of property and equipment
= Free cash flow 34.52M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IRTC
this stock
iRhythm Holdings, Inc.
|
$4.11B | -27.9% | +26.2% | — | 9.7% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -48.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IRTC | +3.9% | +18.9% | -4.3% | +9.2% | -27.9% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +5.9% | +15.6% | -15.5% | +7.2% | -39.7% |
Key facts
CIK
1388658
CUSIP
450056106
13F (30d)
285 filings
280 filers
Visit website
Investor relations